Burning Rock Biotech Ltd (BNR)

Currency in USD
6.6000
+0.4900(+8.02%)
Real-time Data·
BNR Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
BNR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
6.45007.7899
52 wk Range
2.18009.4800
Key Statistics
Prev. Close
6.1
Open
6.57
Day's Range
6.45-7.7899
52 wk Range
2.18-9.48
Volume
35.43K
Average Volume (3m)
47.19K
1-Year Change
-5.13%
Book Value / Share
7.68
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BNR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Burning Rock Biotech Ltd Company Profile

Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for non-small cell lung cancer (NSCLC) patients; OncoScreen Plus, a pan-cancer test for tissue samples; OncoCompass Plus, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers. The company also provides CanCatch, a pre-operative ctDNA detection and post-operative minimal residual disease calling for relapsed patients; OncoMaster, an automatic NGS data analysis and report interpretation machine; as well as Magnis BR-customized version of its key products. In addition, it engages in the facilitation of laboratory equipment sales and sales of reagent kits. The company has a development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. Burning Rock Biotech Limited was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.

Burning Rock Biotech Ltd Earnings Call Summary for Q4/2024

  • Brentag SE reported €16.2B in sales for 2024, down 3% YoY, with operating EBITA declining 13% to €1.1B amid economic challenges
  • Cost containment program achieved €50M in savings; company maintains strong liquidity with a current ratio of 3.04
  • Guidance for 2025 operating EBITA: €1.0-1.2B, expecting moderate volume improvements and better pricing environment
  • CEO emphasized resilient cash generation and strong balance sheet; CFO highlighted successful cost reduction efforts
  • Company faces risks from geopolitical uncertainty, subdued growth, cost pressures, market competition, and regulatory changes
Last Updated: 12/03/2025, 15:30
Read Full Transcript

Compare BNR to Peers and Sector

Metrics to compare
BNR
Peers
Sector
Relationship
P/E Ratio
−2.0x−14.5x−0.5x
PEG Ratio
−0.03−0.110.00
Price/Book
0.8x5.3x2.6x
Price / LTM Sales
0.9x24.3x3.3x
Upside (Analyst Target)
-156.3%43.5%
Fair Value Upside
Unlock−5.6%6.9%Unlock

Earnings

Latest Release
Jun 06, 2025
EPS / Forecast
-1.25 / --
Revenue / Forecast
133.08M / --
EPS Revisions
Last 90 days

BNR Income Statement

People Also Watch

17.41
SRPT
+7.07%
44.610
SMR
-2.87%
2.2001
DARE
-2.65%
1.540
AACG
-3.75%

FAQ

What Stock Exchange Does Burning Rock Trade On?

Burning Rock is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Burning Rock?

The stock symbol for Burning Rock is "BNR."

What Is the Burning Rock Market Cap?

As of today, Burning Rock market cap is 71.06M.

What Is Burning Rock's Earnings Per Share (TTM)?

The Burning Rock EPS (TTM) is -22.90.

From a Technical Analysis Perspective, Is BNR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Burning Rock Stock Split?

Burning Rock has split 1 times.

How Many Employees Does Burning Rock Have?

Burning Rock has 674 employees.

What is the current trading status of Burning Rock (BNR)?

As of 07 Aug 2025, Burning Rock (BNR) is trading at a price of 6.60, with a previous close of 6.10. The stock has fluctuated within a day range of 6.45 to 7.79, while its 52-week range spans from 2.18 to 9.48.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.